Multiple studies have uncovered that the Pfizer and Moderna vaccines don’t protect people against COVID-19 for an extended period, especially with the Omicron variant.
A study published in JAMA Network Open in May found that the Pfizer vaccine’s efficacy rapidly declined only weeks after patients received their second and third doses.
“Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses of BNT162b2,” researchers write.
According to the research, Omicron-specific neutralizing antibody responses “plummeted rapidly” from 76.2 percent during the fourth week down to 53.3 percent by weeks 8-10 and then decreased to 18.9 percent by weeks 12-14, compared with Delta.
In other words, the Pfizer vaccine lost almost all of its effectiveness after three months.
“A limitation of our study is that its cross-sectional design precludes evaluation of antibody decrease rates on an individual level. Nevertheless, the observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction–confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom.”
Researchers have found that the Pfizer vaccine only provides “transient” immunity, meaning that people may need to receive eve more “transient” booster doses.
“Taken together, vaccine-induced protective antibody responses following a second and third dose of BNT162b2 are transient, and additional booster doses may be necessary, particularly in older people; however, conserved T-cell immunity and non-neutralizing antibodies may still provide protection against hospitalization and death,” researchers say.
The findings are consistent with those of a study on the Moderna vaccine, which revealed that persons vaccinated with Moderna’s mRNA vaccination were more likely to be reinfected, possibly indefinitely, than people who gained natural immunity.
The study’s researchers analyzing the vaccine efficacy of Moderna looked at 1,789 participants (1,298 placebo recipients and 491 vaccine recipients) that were 18 years old or older with no known history of SARS-CoV-2 infection and at appreciable risk of SARS-CoV-2 infection and/or high risk of severe Covid-19. They found that those not inoculated with Moderna had more antibodies after being infected than those who received the vaccine.
“Among participants in the mRNA-1273 vaccine efficacy trial with PCR-confirmed Covid-19, anti-nucleocapsid antibody seroconversion at the time of study unblinding (median 53 days post-diagnosis and 149 days post-enrollment) occurred in 40% of the mRNA-1273 vaccine recipients vs. 93% of the placebo recipients, a significant difference,” the researchers conclude.
According to Children’s Health Defense, “Anti-nucleocapsid antibodies are antibodies specific to the nucleocapsid portion of the SARS-CoV-2 virus, the virus responsible for COVID-19.”
Furthermore, the findings from Moderna’s vaccine recipients showed that they are more likely to be reinfected, with no end in sight.
“The authors’ findings, which are corroborated by U.K. data that demonstrate the rates of infection are significantly higher in the vaccinated, suggest Moderna knew of this safety signal in 2020 when the vaccine maker was conducting its trials,” writes Children’s Health Defense.
“…. Specifically, the study implies that the reduced ability of a vaccinated individual to produce antibodies to other portions of the virus may lead to a greater risk of future infections in the vaccinated compared to the unvaccinated.”
The researchers’ findings suggest that natural infection is likely to provide more robust protection against future exposure to COVID-19.
As for AstraZeneca, the weakening vaccine effectiveness is a serious fault of the vaccination.
Reporting on a study published in The Lancet, the University of Edinburgh says, “In Scotland, when compared with two weeks after receiving a second dose, there was approximately a fivefold increase in the chance of being hospitalized or dying from Covid-19 nearly five months after being double vaccinated.”
“The decline in effectiveness begins to first appear at around three months, when the risk of hospitalization and death is double that of two weeks after the second dose, experts say.”
“The risk increases threefold just short of four months after the second vaccine dose. Similar numbers were seen for Brazil.”
What about the Johnson & Johnson vaccine? Surely, one of the four big COVID vaccines offer adequate protection for more than six months. Unfortunately, that is not the case!
The Johnson and Johnson vaccine, according to a study published by medRxiv, loses 88 percent effectiveness after six months. According to Medical & Life Sciences News, the efficacy of vaccines drops from 88% to 3% after six months, the worst of the big four COVID vaccines.
None of the four most commonly administered vaccines offers long-term protection.